Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients

Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients

Nonalcoholic fatty liver disease (NAFLD) refers to excess fat accumulation in the liver. In animal experiments and human kinetic study, we found that administration of combined metabolic activators (CMAs) promotes the oxidation of fat, attenuates the resulting oxidative stress, activates mitochondri...

Full description

Bibliographic Details
Main Authors: Akyildiz, M. (Author), Altay, O. (Author), Arif, M. (Author), Borén, J. (Author), Fredolini, C. (Author), Gonenli, M.G (Author), Kim, W. (Author), Li, X. (Author), Mardinoglu, A. (Author), Nielsen, J. (Author), Saglam, B. (Author), Schwenk, J.M (Author), Shoaie, S. (Author), Uhlén, M. (Author), Ural, D. (Author), Yang, H. (Author), Zeybel, M. (Author), Zhang, C. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2021
Subjects:
acetylcysteine
adult
aged
alanine aminotransferase
animal
Animals
Article
aspartate aminotransferase
body weight loss
C57BL mouse
carnitine
carnitine tartrate
clinical article
clinical study
CMA
controlled study
creatinine
Diet, High-Fat
drug efficacy
drug safety
evening dosage
fat
fatty acid oxidation
fatty acid transport
fatty liver
female
follow up
gastrointestinal symptom
host microbe interaction
human
Humans
inflammation
Inflammation
lipid diet
liver
Liver
male
metabolomics
metagenomics
Mice
Mice, Inbred C57BL
morning dosage
mouse
multiomics
multi-omics
musculoskeletal disease
NAFLD
network analysis
nicotinamide riboside
nonalcoholic fatty liver
Non-alcoholic Fatty Liver Disease
phase 2 clinical trial
placebo
proteomics
randomized controlled trial
serine
systems biology
unclassified drug
uric acid
Weight Loss
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items